PDF(Pubmed)
Abstract：
UNASSIGNED: Esthesioneuroblastoma (ENB) is an uncommon malignant sinonasal tumor. There are few data regarding ENB management, namely its treatment. We review our institute\'s experience in the treatment of ENB and evaluate survival outcomes.
UNASSIGNED: Retrospective study of patients with ENB treated between 1984-2022. A total of 20 patients were identified, 13 men and 7 women, aged between 20 and 76 years.
UNASSIGNED: Eleven patients were stage C of the modified Kadish staging system at initial presentation, 7 stage B, 1 stage A and 1 stage D. Seventeen patients underwent surgery alone or combined with adjuvant treatment (radiotherapy or chemoradiotherapy). The majority of the patients (71.4%) treated with surgery alone were stage B, whereas most of the patients (63.6%) that underwent surgery combined with adjuvant treatment were stage C. Five of the 7 patients treated with surgery alone had a locoregional recurrence. Two of the 10 patients treated with surgery followed by adjuvant treatment had relapsed, locoregionally and at a distance, respectively. One patient was treated with chemotherapy and 2 patients were treated with chemoradiotherapy and neoadjuvant chemotherapy followed by chemoradiotherapy, respectively. The recurrence and persistence rates were 35% and 15%, respectively. The median time from the end of the first treatment to recurrence was 20.9 months. Two- and 5-year overall survival rates were 83.9% and 77.9%; while progression-free survival rates were 76.7% and 61.0%, respectively.
UNASSIGNED: Sixty percent of patients were treated with a multimodal approach, which appeared to be a favorable strategy for the majority of patients.
UNASSIGNED: Retrospective study of patients with ENB treated between 1984-2022. A total of 20 patients were identified, 13 men and 7 women, aged between 20 and 76 years.
UNASSIGNED: Eleven patients were stage C of the modified Kadish staging system at initial presentation, 7 stage B, 1 stage A and 1 stage D. Seventeen patients underwent surgery alone or combined with adjuvant treatment (radiotherapy or chemoradiotherapy). The majority of the patients (71.4%) treated with surgery alone were stage B, whereas most of the patients (63.6%) that underwent surgery combined with adjuvant treatment were stage C. Five of the 7 patients treated with surgery alone had a locoregional recurrence. Two of the 10 patients treated with surgery followed by adjuvant treatment had relapsed, locoregionally and at a distance, respectively. One patient was treated with chemotherapy and 2 patients were treated with chemoradiotherapy and neoadjuvant chemotherapy followed by chemoradiotherapy, respectively. The recurrence and persistence rates were 35% and 15%, respectively. The median time from the end of the first treatment to recurrence was 20.9 months. Two- and 5-year overall survival rates were 83.9% and 77.9%; while progression-free survival rates were 76.7% and 61.0%, respectively.
UNASSIGNED: Sixty percent of patients were treated with a multimodal approach, which appeared to be a favorable strategy for the majority of patients.
摘要：
■鼻腔神经母细胞瘤（ENB）是一种罕见的恶性鼻窦肿瘤。关于ENB管理的数据很少，即它的治疗。我们回顾了我们研究所在ENB治疗方面的经验，并评估了生存结果。
■1984-2022年间接受ENB治疗的患者的回顾性研究。总共确定了20名患者，13男7女,年龄在20至76岁之间。
■11例患者在初次就诊时处于改良Kadish分期系统的C期，7阶段B，1期A和1期D。17例患者接受了单独手术或联合辅助治疗（放疗或放化疗）。仅接受手术治疗的大多数患者（71.4％）为B期，而接受手术联合辅助治疗的大多数患者(63.6%)为C期,仅接受手术治疗的7例患者中有5例局部复发.手术后辅助治疗的10例患者中有2例复发，局部和远处，分别。1例患者接受化疗，2例患者接受放化疗和新辅助化疗，然后进行放化疗。分别。复发率和持续率分别为35%和15%，分别。从首次治疗结束到复发的中位时间为20.9个月。2年和5年总生存率分别为83.9%和77.9%，无进展生存率分别为76.7%和61.0%，分别。
■60%的患者接受了多模式治疗，这似乎是对大多数患者有利的策略。
■1984-2022年间接受ENB治疗的患者的回顾性研究。总共确定了20名患者，13男7女,年龄在20至76岁之间。
■11例患者在初次就诊时处于改良Kadish分期系统的C期，7阶段B，1期A和1期D。17例患者接受了单独手术或联合辅助治疗（放疗或放化疗）。仅接受手术治疗的大多数患者（71.4％）为B期，而接受手术联合辅助治疗的大多数患者(63.6%)为C期,仅接受手术治疗的7例患者中有5例局部复发.手术后辅助治疗的10例患者中有2例复发，局部和远处，分别。1例患者接受化疗，2例患者接受放化疗和新辅助化疗，然后进行放化疗。分别。复发率和持续率分别为35%和15%，分别。从首次治疗结束到复发的中位时间为20.9个月。2年和5年总生存率分别为83.9%和77.9%，无进展生存率分别为76.7%和61.0%，分别。
■60%的患者接受了多模式治疗，这似乎是对大多数患者有利的策略。
